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UDP-Glucuronosyltransferase (UGT) Genetic Variants and their Potential Role in 
Carcinogenesis  
 
Jean Bendaly 
 
ABSTRACT  
Exposure to polycyclic aromatic hydrocarbons (PAHs) such as benzo(a)pyrene  
are important risk factors for cancer.  Three UDP-glucuronosyltransferases, UGT1A9,  
UGT1A10, and UGT2B7, have been shown to play an important role in the phase II  
metabolism of carcinogenic metabolites of BaP.  Because UGT1A9 and UGT2B7 are  
well-expressed in digestive tract tissues including liver and colon, it is possible that  
genetic variations in either enzyme may play an important role in colon cancer risk.   
However, UGT1A10 is extrahepatic and is expressed in the oral cavity and the larynx;  
therefore, genetic variations in this enzyme may play an important role in risk for  
orolaryngeal cancer. This study examined UGT1A9-, UGT1A10-, and UGT2B7-specific  
sequences for polymorphisms that play a role in cancer susceptibility.  For the UGT1A9  
gene, two missense polymorphisms at codons 167 (Val>Ala) and 183 (Cys>Gly) were  
identified.  A previously-reported missense polymorphism was identified for the  
UGT2B7 gene.  To assess the potential role of UGT1A10 variants as a risk factor for  
orolaryngeal cancer, PCR-RFLP was used to identify UGT1A10 genotypes in DNA  
specimens isolated from 115 African American newly-diagnosed orolaryngeal cancer  
cases and 115 non-cancer controls individually matched by age and race.  A significantly  
decreased risk for orolaryngeal cancer was observed for subjects possessing one or more  
UGT1A10139Lys alleles as determined by crude analysis or after logistic regression  
analysis adjusting for age, sex, smoking and alcohol consumption.  These results strongly  
 viii
suggest that the UGT1A10139Lys polymorphism may play an important protective role in  
risk for orolaryngeal cancer.  To determine whether the change in amino acid sequence  
at codon 183 results in aberrant UGT1A9 enzyme activity, functional characterization of  
the wild-type- and variant-encoded UGT1A9 isoforms was performed in vitro.  Cell  
homogenates were prepared from UGT1A9-transfected HK293 cells and glucuronidation  
assays were performed against various carcinogens/carcinogen metabolites.  A significant  
(p<0.001) 3- to 4-fold decrease in enzyme activity, determined by HPLC analysis, was  
observed for the UGT1A9183Gly variant as compared to its wild-type counterpart for all  
substrates analyzed.  These results demonstrate that the UGT1A9 (Cys183Gly)  
polymorphism significantly alters UGT1A9 function and could potentially play an  
important role as risk modifier for digestive tract cancers. 
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LITERATURE REVIEW 
 
From Genes to Proteins 
 
Genes, the basic unit of inheritance, are contained in chromosomes and consist of  
 
deoxyribonucleic acid (DNA) which provides the genetic “blue-print” for all proteins  
 
in the body (Lebowitz et al., 1990).  Thus, genes ultimately influence all aspects of body  
 
structure and function.  The human is estimated to have 50,000 to 100,000 structural  
 
genes (genes that code for proteins).  An error or mutation in one of these genes often  
 
leads to a recognizable genetic disease (Jackson et al., 1991).  
 
The DNA molecule has three basic components: the pentose sugar, deoxyribose; a  
 
phosphate group; and four types of nitrogenous bases.  Two of these bases, cytosine  
 
and thymine, are single carbon-nitrogen rings called pyrimidines.  The other two   
 
bases, adenine and guanine, are double carbon-nitrogen rings called purines.  The four  
 
bases are commonly represented by their first letters: C, T, A, and G (Adams et al.,  
 
1986).   
 
DNA has a double helix structure (Figure 1), in which the sugar and phosphate  
 
components are held together by strong phosphodiester bonds, and the nitrogenous  
 
bases projecting from each side are bound to each others by relatively weak hydrogen  
 
bonds (Dickerson et al., 1983; Travers et al., 1989).  Each DNA subunit, consisting of  
 
one deoxyribose, one phosphate group, and one base, is called a nucleotide (Figure 2).   
 
When referring to the orientation of sequences along a gene, the 5’ direction is termed  
 
“upstream”, while the 3’ direction is termed “downstream” (Rich et al., 1984). 
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Figure 1.  Double helix structure of DNA (National Institutes of Health, DNA, n.d.) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3
 
 
 
 
 
 
 
 
 
 
Figure 2.  Base pairing in DNA showing Adenine, Thymine, Guanine, and Cytosine 
(represented by A, T, G, and C respectively); and DNA subunit, consisting of one 
deoxyribose, one phosphate group, and one base, called a nucleotide (National Institutes 
of Health, Base pair, n.d.) 
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While DNA is formed and replicated in the cell nucleus, protein synthesis takes  
 
place in the cytoplasm.  The information contained in DNA must then be transported to  
 
the cytoplasm and then used to dictate the composition of proteins.  This involves two  
 
processes, transcription and translation.   
 
Transcription is the process by which an RNA sequence is formed from a DNA  
 
template.  The type of RNA produced by the transcription process is termed messenger  
 
RNA (mRNA).  To initiate mRNA transcription, one of the RNA polymerase (RNA  
 
polymerase II) binds to a promoter site on the DNA (a promoter is a nucleotide sequence  
 
that is located just upstream of a gene).  The RNA polymerase then pulls a portion of the  
 
DNA strands apart from one another, exposing unattached DNA bases (Conaway et al.,  
 
1991; Mermelstein et al., 1989).  One of the two DNA strands provides the template for  
 
the sequence of mRNA nucleotides.  Since mRNA can be synthesized only in the 5’ to 3’  
 
direction, the promoter, by specifying directionality, determines which DNA strand  
 
serves as the template.  RNA polymerase moves in the 3’ to 5’ direction along the DNA  
 
template strand, assembling the complementary mRNA strand from 5’ to 3’. 
 
Soon after RNA synthesis begins, the 5’ end of the growing RNA molecule is  
 
“capped” by the addition of a chemically modified guanine nucleotide (Simpson et al.,  
 
1990).  This 5’ cap appears to help to prevent the RNA molecule from being degraded  
 
during synthesis, and later it helps to indicate the starting position for translation of the  
 
mRNA molecule into protein.  Transcription continues until a group of bases called a  
 
termination sequence is reached.  Near this point, a series of 100 to 200 adenine bases  
 
are added to the 3’ end of the RNA molecule.  This structure, known as the poly-A  
 
tail, may be involved in stabilizing the mRNA molecule so that it is not degraded  
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when it reaches the cytoplasm (Bernstein et al., 1989; Manley et al., 1988; Wickens et al.,  
 
1990).  Finally, the DNA strands and RNA polymerase separate from the RNA strand,  
 
leaving a transcribed single mRNA strand.  This mRNA molecule is termed the primary  
 
transcript (Wahle et al., 1992). 
 
The primary mRNA transcript is exactly complementary to the base sequence of  
 
the DNA template.  In eukaryotes (eukaryotes are organisms that have a defined cell  
 
nucleus, as opposed to prokaryotes, which lack a defined nucleus), an important step  
 
takes place before this RNA transcript leaves the nucleus; sections of the RNA are  
 
removed by nuclear enzymes, and the remaining sections are spliced together to form  
 
the functional mRNA that will migrate to the cytoplasm (Agabian et al., 1990; Green et  
 
al., 1991; Maniatis et al., 1991).  The excised sequences are called introns, and the  
 
sequences that are left to code for proteins are called exons (Patthy et al., 1991; Shapiro  
 
et al., 1987; Figure 3).  When gene splicing is completed, the mature transcript moves out  
 
of the nucleus into the cytoplasm (Figure 4).  Some genes contain alternative splice sites,  
 
which allow the same  primary transcript to be spliced in different ways, therefore  
 
producing different protein products from the same gene (Guthrie et al., 1988). 
 
Proteins are composed of one or more polypeptides, which are in turn composed  
 
of sequences of amino acids.  The body contains 20 different types of amino acids, and  
 
the amino acid sequences that make up polypeptides must in some way be designated  
 
by the DNA after transcription into mRNA.  Individual amino acids, which compose  
 
proteins, are encoded units of three mRNA bases, termed “codons” (Fox et al., 1987;  
 
Lagerkrist et al., 1987).  Of the 64 possible codons, 3 signal the end of a gene and are  
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Figure 3.  RNA synthesis and processing (National Institutes of Health, RNA synthesis 
and processing, n.d.) 
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Figure 4.  Mature RNA transcript transported to cytoplasm for protein synthesis (National 
Institutes of Health, mRNA, n.d.) 
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known as stop codons.  The remaining 61 all specify amino acids; this means that most  
 
amino acids can be specified by more than one codon (Figure 5).   
 
Translation is the process in which mRNA provides a template for the synthesis  
 
of a polypeptide (Merrick et al., 1992).  mRNA can not, however, bind directly to amino  
 
acids; instead, it interacts with transfer RNA (tRNA), a cloverleaf-shaped RNA strand of  
 
about 80 nucleotides (Burbaum et al., 1991).  As Figure 5 illustrates, the tRNA molecule  
 
has a site at its 3’ end for the attachment of an amino acid by a covalent bond.  At the  
 
opposite end of the cloverleaf is a sequence of three nucleotides called the anticodon.  
 
This sequence complementary base pairs with an appropriate codon in the mRNA (Mlot  
 
et al., 1989).   
 
The cytoplasmic site of protein synthesis is the ribosome, which consists of  
 
almost equal parts of enzymatic proteins and ribosomal RNA (rRNA).  The function of  
 
rRNA is to help to bind mRNA and tRNA to the ribosome.  During translation, the  
 
ribosome first binds to an initiation site on the mRNA sequence; the site consists of a  
 
specific codon, AUG, which specifies the amino acid methionine (which is removed from  
 
the polypeptide before the completion of polypeptide synthesis).  The ribosome then  
 
binds the tRNA to its surface so that base pairing can occur between tRNA and mRNA.   
 
The ribosome moves along the mRNA sequence, codon by codon, in the usual 5’ to 3’  
 
direction; as each codon is processed, an amino acid is translated by the interaction of  
 
mRNA and tRNA (Noller et al., 1991). 
 
In this process, the ribosome provides an enzyme that catalyzes the formation of  
 
covalent peptide bonds between the adjacent amino acids, resulting in a growing   
 
polypeptide.  When the ribosome arrives at a stop codon on the mRNA sequence,  
 9
 
 
 
 
 
 
 
 
Figure 5.  The genetic code and the cloverleaf-shaped transfer RNA (tRNA) strand 
(National Institutes of Health, The genetic code, n.d.) 
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translation and polypeptide formation cease.  The amino (NH2) terminus of the  
 
polypeptide corresponds to the 5’ end of the mRNA strand, and the carboxyl (COOH)  
 
terminus corresponds to the 3’ end.  With synthesis completed, the mRNA, ribosome,  
 
and polypeptide separate from one another; the polypeptide (Figure 6) is then released  
 
 into the cytoplasm (Dahlberg et al., 1989). 
 
Before a newly synthesized polypeptide can begin its existence as functional   
 
protein, it often undergoes further processing, termed post-translational modification  
 
(Neurat et al., 1989).  These modifications can take a variety of forms, including cleavage  
 
into smaller polypeptide units or combination with other polypeptides to form proteins.   
 
Other possible modifications include the addition of carbohydrate side chains to the  
 
polypeptide (Yan et al., 1989).  These modifications are needed, for example, to produce  
 
proper folding of the mature protein or to stabilize its structure (Baldwin et al., 1989;  
 
Creighton et al., 1992; Gethway et al., 1992).     
 
Xenobiotic Metabolism and UDP-Glucuronosyltransferases (UGTs) 
Biotransformation is important in maintaining homeostasis during exposure of  
organisms to foreign substances, such as pharmaceuticals and xenobiotics.  It is  
accomplished by a number of enzymes with broad substrate specificities.  The reactions  
catalyzed by these enzymes are divided into two broad categories, called phase I and  
phase II (Williams et al., 1971).  Phase I reactions include, for example, hydrolysis,  
reduction, and oxidation, and usually expose or introduce a functional group (e.g., -NH2,  
-OH, -SH or -COOH) onto the molecule thereby increasing its hydrophilicity.  Phase II  
reactions include, for example, glucuronidation, sulfation, acetylation, methylation,  
 11
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Primary polypeptide chain (National Institutes of Health, Amino acid, n.d.) 
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glutathione conjugation, and conjugation with amino acids.  Most phase II reactions  
result in a large increase in xenobiotic hydrophilicity, thus promoting the excretion of  
foreign compounds. 
Glucuronidation, sulfation, acetylation, and methylation involve reactions with  
high energy cofactors such as “acetyl coenzyme A” and “3’-phosphoadenosine-5’- 
phosphosulfate” ( also known as PAPS), whereas conjugation with amino acids or  
glutathione generally do not.  Most phase II enzymes are found in the cytosol, except for  
the UDP-glucuronosyltransferases, which are microsomal enzymes.  Phase II reactions  
generally proceed much faster than phase I reactions (for example, those catalyzed by  
cytochrome P-450).   
Most metabolism of ingested xenobiotics occurs in the liver.  Absorbed chemicals  
must first pass through the liver before entering the general circulation.  Catalytic  
reactions are facilitated by one of several conjugation reactions leading to the elimination  
of the resultant metabolites from the cell.  Detoxification of lipophilic xenobiotics is  
efficiently performed by the phase II conjugation reactions, thus making them more  
water-soluble to facilitate elimination, primarily by the kidney.   
Glucuronide conjugation reactions of both xenobiotic and endogenous substrates  
is an important mechanism of detoxification and elimination (Tukey et al., 2000; Tephly  
et al., 1990; Gueraud et al., 1998).  Glucuronide formation is catalyzed by a family of  
UDP-glucuronosyltransferases (UGTs) which are localized in the endoplasmic reticulum  
of liver and other tissues, such as the kidney, intestine, skin, brain, spleen, and nasal  
mucosa.  UGTs utilize uridine diphosphate-glucuronic acid (UDP-GA) as co-substrate for  
the formation of glucuronides (Figure 7).   
 13
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Figure 7.  Uridine diphosphate-glucuronic acid (UDP-GA) used as co-substrate for the 
formation of glucuronides in reactions utilizing UGTs   
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The UGT isoenzymes are derived from a multigene family.   Based upon  
differences in sequence homology and substrate specificity, two major families (UGT1A  
and UGT2B) have been identified in several species, each containing several highly  
homologous UGT genes.  The UGT protein sequences exhibit greater than 60% similarity  
within a single family.   
The members of the UGT1A gene family, which comprises phenol- and bilirubin- 
metabolizing isoforms, all share an identical 246 amino acid carboxy terminus (Owens et  
al., 1995), whereas the N-terminus of the enzyme can vary.  In contrast, members of the  
UGT2B gene family, the steroid-metabolizing isoforms, show little conservation among  
the different isoforms of this family (Tukey et al., 2000). 
The entire UGT1A family is derived from a single locus on chromosome 2 coding  
for nine functional proteins (Table 1). Each of the UGT1A proteins is encoded by five  
exons, with exons 2 to 5 conserved in all of the isoforms.  The DNA sequence encoding  
exons 2 to 5 is located at the 3’ portion of the locus.  The sequences that encode the exon  
1 portions of the UGTs are composed of blocks of DNA that exist as cassettes and are  
aligned in series upstream of exon 2 (Figure 8).  Each functional exon 1 cassette is  
composed of a transcriptional start site and a 5’ consensus spliceosome recognition  
sequence at the 3’ -end of the cassette.    The cassettes are separated from each other by  
15,000 to 25,000 base pairs.  Flanking each cassette in the 5’ –direction are functional  
promoter elements that are important for transcription (Tukey et al., 2000). 
In contrast to the UGT1A family, the UGT2B family is composed of several  
independent genes, coding for seven known functional human UGT enzymes clustered on  
chromosome 4 (Jin et al., 1993; Beaulieu et al., 1997; Beaulieu et al., 1998; Belanger et  
 15
 
 
 
 
 
 
Isoforms of UGT1A Family Isoforms of UGT2B Family 
1A1 2B4 
1A3 2B7 
1A4 2B10 
1A5 2B15 
1A6 2B17 
1A7 2B28 
1A8  
1A9  
1A10  
Table 1.  Family 1 and family 2 UGT proteins  
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Figure 8.  UGT1A exon 1’s and exons 2-5 (Ritter et al., 1992) 
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al., 1998; Carrier et al., 2000).  The UGT2 genes are composed of six exonic sequences  
(Figure 9). 
In previous studies (Srassburg et al., 2000; Zheng et al., 2002), several UGTs  
including UGT1A9 and UGT2B7 were shown to be expressed in liver as well as in  
tissues of the digestive tract including colon and esophagus (Table 2), and to play an  
important role in the phase II metabolism of procarcinogenic metabolites of  
benzo[a]pyrene (BaP) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).  In  
addition, UGT1A10 has been shown to be expressed in many target tissues for tobacco- 
related cancers including the upper digestive and respiratory tracts (Table 2), and to  
exhibit high activity against several BaP metabolites, including BaP-7,8-dihydrodiol.  
The nicotine derived nitrosamine, NNK, is one of the most potent and abundant  
procarcinogens found in tobacco and tobacco smoke (Hecht et al., 1989; Hecht et al.,   
1998).  NNK levels in tobacco smoke are 3- 15 times higher than that of another major  
potent carcinogen in tobacco smoke, benzo[a]pyrene (Adams et al., 1987).  In one  
study, NNK induced predominantly lung adenocarcinomas in rodents independent of the  
route of administration (Hecht et al., 1998).  Another study in the Fischer 344 rat, NNK  
induced pancreatic tumors (Rivenson et al., 1988) and, when applied together with the  
related tobacco-specific nitrosamine, N’-nitrosonornicotine, oral cavity tumors (Hecht et  
al., 1986).  The cumulative dose of 1.8 mg NNK/kg body weight required to produce  
lung tumors in rodents (Belinsky et al., 1990) is similar to the cumulative lifetime dose of  
1.6 mg NNK/kg body weight for the average American smoking two packs of cigarettes a 
day for 40 years (Hecht et al., 1989; Hecht et al., 1998).  NNK is therefore considered to 
be a likely causative agent for several tobacco-related cancers in humans including those  
 18
 
 
 
 
 
Figure 9.  UGT2B exons 1-6 
 
 
 
 
 
 
 
 
 
 
   Exon I           II           III                              IV       V                 VI 
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UGT 
 
 
Liver 
 
Colon 
 
Lung 
 
Breast 
 
Prostate 
Upper 
Digestive & 
Respiratory 
Tracts 
 
1A9 
 
 
+ 
 
+ 
 
- 
 
- 
 
- 
 
- 
 
1A10 
 
 
- 
 
- 
 
+ 
 
- 
 
- 
 
+ 
 
2B7 
 
 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
 
- 
 
Table 2.  Expression of UGT1A9, UGT1A10 and UGT2B7 (Zheng et al., 2002; 
Strassburg et al., 2000)   
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of the lung, oral cavity, bladder, and pancreas (Hecht et al., 1998; Rivenson et al., 1988 ). 
The major metabolic pathway of NNK in most tissues is carbonyl reduction to  
NNAL (Figure 10).  NNK reduction to NNAL occurs in rodents, monkeys, and humans  
(Hecht et al., 1998; Carmella et al., 1993; Hecht et al., 1993).  It was estimated that  
between 39-100% of the NNK dose is converted to NNAL in smokers (Carmella et al.,  
1993).  NNAL is activated via pathways similar to those observed for NNK and, like  
NNK, is a potent lung and pancreatic carcinogen in rodents (Hecht et al., 1998; Rivenson  
et al., 1988).  Previous studies have shown that NNAL is also metabolized to its  
glucuronide conjugate, NNAL-Gluc (Hecht et al., 1998; Carmella et al., 1993; Hecht et  
al., 1993; Morse et al., 1990; Ren et al., 2000; Hecht et al., 1999).  Although the  
formation of NNAL is not a detoxification pathway for NNK, the glucuronidation of  
NNAL appears to be an important mechanism for NNK detoxification. 
NNAL glucuronidation can occur at both the carbinol group (NNAL-O-Gluc;  
Hecht et al., 1998; Carmella et al., 1993; Hecht et al., 1993; Morse et al., 1990; Ren et al.,  
2000; Figure 11) and the nitrogen on NNAL’s pyridine ring (NNAL-N-Gluc; Carmella et  
al., 2002).  NNAL-O-Gluc formation in human tissues is well-characterized and was  
found to be mediated primarily by the hepatic enzymes, UGT2B7 and UGT1A9 (Ren et  
al., 2000).  The identification of NNAL-N-Gluc in human urine has been recently  
reported (Carmella et al., 2002), and shown that its formation is mediated exclusively by  
the hepatic enzyme, UGT1A4 (Wiener et al., 2004). 
Benzo[a]pyrene is a much-studied polycyclic aromatic hydrocarbon that exhibits  
high carcinogenicity in animals and is found widespread in the environment including in  
emission exhausts, cigarette smoke, and char-broiled foods (Gelboin et al., 1980; IARC,  
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Figure 10.  Tobacco-specific nitrosamine metabolism (Hecht et al., 1998) 
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Figure 11.  Simplified schematic of NNK metabolism to NNAL-Gluc (A) and structures 
of NNAL and NNAL-Gluc rotamers and enantiomers (Hecht et al., 1998)   
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General remarks 1983; Dipple et al., 1990).  This carcinogen is metabolized by phase I  
enzymes to a large number of metabolites (Figure 12) including phenols, arene oxides,  
quinones, dihydrodiols, and diol epoxides, and is also conjugated by phase II enzymes  
with glutathione, sulfate, and glucuronic acid to form more water-soluble, detoxified  
derivatives (Gelboin et al., 1980).   
Although several of these metabolites contribute to the high carcinogenicity of  
BaP, many studies have clearly identified the 7,8-diol-9,10-epoxide as the primary  
carcinogenic metabolite of BaP, with the anti-(+)-BaP-7R,8S-dihydrodiol-9S,10R- 
epoxide diastereomer exhibiting enhanced mutagenic activity in vitro and in vivo  
(Gelboin et al., 1980; IARC, General remarks 1983; Borgen et al., 1973; Huberman et al.,  
1976; Newbold et al., 1976; Slaga et al., 1976; Yang et al., 1977).  This ultimate  
carcinogen is formed from BaP by two P450-mediated oxidations separated by a  
hydrolysis reaction involving epoxide hydrolase-mediated formation of the proximate  
carcinogen, BPD (Figure 13).   
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Figure 12.  Benzo[a]pyrene metabolism (Gelboin et al., 1980) 
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Figure 13.  Simplified schematic of BaP metabolism to BPD glucuronides and structures 
of potential BPD glucuronide regioisomers and diastereomers (Gelboin et al., 1980) 
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CHAPTER ONE 
 
DETECTION OF UGT1A10 POLYMORPHISMS AND THEIR ASSOCIATION 
WITH OROLARYNGEAL CARCINOMA RISK 
Abstract 
UGT1A10 has been implicated as an important detoxifying enzyme for tobacco  
carcinogens including benzo[a]pyrene.  The UGT1A10 codon 244 (Leu>Ile) and codon  
139 (Glu>Lys) missense polymorphisms are present at a low prevalence in Caucasians  
but at a significantly higher prevalence in African Americans.  To assess the potential  
role of UGT1A10 variants as a risk factor for orolaryngeal cancer, PCR-RFLP was used  
to identify UGT1A10 genotypes in buccal cell DNA specimens isolated from 115 African  
American newly-diagnosed orolaryngeal cancer cases and 115 non-cancer controls  
individually matched by age and race.  The prevalence of the UGT1A10244Ile and  
UGT1A10139Lys polymorphisms in African American controls were 0.05 and 0.07,  
respectively.  A significantly decreased risk for orolaryngeal cancer was observed for  
subjects possessing one or more UGT1A10139Lys alleles as determined by crude analysis  
or after logistic regression analysis adjusting for age, sex, smoking and alcohol  
consumption.  No association with risk for orolaryngeal cancer was observed for the  
UGT1A10244Ile polymorphic variant.  These results strongly suggest that the  
UGT1A10139Lys polymorphism may play an important protective role in risk for  
orolaryngeal cancer. 
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Materials and Methods 
 
Study Population 
This protocol was approved by the USF Institutional Review Board and  
collaborating institutions governing the rules concerning the use of human subjects in  
research.  For the identification of UGT1A10 polymorphisms and the determination of  
prevalence in different racial groups, our subject population included the following: 1)  
162 whites and 110 African Americans from New York City and 2) 200 whites, 79  
African Americans, and 69 Asians (35 of Indian descent and 34 of East Asian descent)  
from Tampa, FL.  These individuals were participants in previous studies of genetic  
polymorphisms and other risk factors for aerodigestive tract carcinoma (Richie et al.,  
1997; Park et al., 2000; Elahi et al., 2002), and tissues were available for this study.    
For this study, the importance of UGT1A10 polymorphisms in the risk for  
orolaryngeal carcinoma was determined for 115 African American cases.  All cases were  
newly diagnosed patients (i.e., they were diagnosed within 1 year before study entry) who  
had histologically confirmed cancer of the tongue (n=21), tonsil (n=11), pharynx or  
hypopharynx (n=9), oral cavity (n=19), mixed sites (n=3), or laryngeal (n=52) squamous  
cell carcinoma.  Controls were recruited between 1996 and 2000 from Temple University  
Hospital (Philadelphia, PA), the New York Eye and Ear Infirmary (New York, NY), and  
the State University of New York at Brooklyn (New York, NY).  Controls were  
outpatients without cancer treated at the ear, nose, and throat or dental clinics of  
participating institutions.  Controls were individually matched to cases based on age  
(within 5 years) and conditions described below.   
To control for biases in demographics or other factors inherent in the recruitment  
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of participants from institutions in different locations, controls also were matched to case  
patients based on the institution of case patient.  Depending on the institute, eligible cases  
were identified either from admission rosters, surgical operating schedules, or cancer care  
listings.  95% of controls and 98% of case patients consented to participation. 
A structured questionnaire that contained items on demographics, life-long  
smoking habits, and other habits was administered by trained interviewers as previously  
described (Park et al., 2000).  Tobacco use was categorized into pack-years.  A pack-year  
is defined as 1 pack of cigarettes per day for 1 year, or 4 cigars per day for 1 year, or 5  
pipes per day for 1 year (Benhamou et al., 1986).  Alcohol consumption was calculated as  
drinks per day.  One drink was defined as 12.9 g of 43% alcohol, which is roughly  
equivalent to 1 oz of 86-proof liquor, or a 3.6 oz glass of wine, or a 12 oz can of beer.   
Study participants were defined as drinkers of alcohol if they reported drinking a  
minimum of 1 drink per week for a minimum of 10 years.  Participants were classified as  
never-drinkers if they consumed 1 or fewer drinks per week, light drinkers from 1 to less  
than 7 drinks per week, moderate drinkers from 7 to less than 28 drinks per week, and  
heavy drinkers 28 or more drinks per week. 
Buccal cell samples were collected from all participants and used for the analysis  
of polymorphic UGT1A10 genotypes.  The same cell type was obtained for genotype  
analysis for all groups.  The cells were then frozen and stored until use in liquid nitrogen. 
 
UGT1A10 Polymerase Chain Reaction Amplification Sequencing and Genotyping  
Analysis 
Cells were thawed and centrifuged in order to obtain a cell pellet.  DNA was  
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isolated from cells by incubating cell pellets with proteinase K (0.1 mg/mL) in 1%  
sodium dodecyl sulfate overnight at 50 °C, extracting with phenol:chloroform, and  
precipitating with ethanol as previously described (Park et al., 2000).  Care was taken  
during DNA purification and isolation to prevent contamination and cross-contamination  
between samples during polymerase chain reaction (PCR).  The purification of DNA  
samples was performed in a location distant from the workstation where PCR  
amplifications were performed.  All equipment used for tissue blending and  
homogenization was washed in a bath of concentrated chromic acid/sulfuric acid, rinsed  
3 times in autoclaved double-distilled water and once in 70% ethanol, air-dried, and  
autoclaved after each sample was processed. 
The family 1A locus comprises divergent and individually regulated exon 1  
sequences that transcribe for mRNAs that are spliced alternatively onto the 5’-end of the  
sequence encoded by the common UGT exons 2-5 region.  Therefore, UGT mRNAs  
consist of a unique region encoded by exon 1 and a region encoded by exons 2-5 that is  
common for all family 1A UGTs.  To evaluate sequences that were UGT1A10 specific  
and that spanned the entire UGT1A10 exon 1 region, the 5’-end of the UGT1A10  
exon 1 (fragment “1”, size = 657 bp) was amplified by PCR using a sense primer  
(1A10S1; 5’-TCCGCCTACTGTATCATAGCA-3’) corresponding to nucleotides  
–61 through –41 relative to the translation start site in UGT1A10 exon 1 (GenBank  
accession numbers AF297093 and HSU89508) and a UGT1A10 exon 1-specific antisense  
primer (1A10AS1; 5’-TCTGAGAACCCTAAGAGATCA-3’) corresponding to  
nucleotides 576-596 of the UGT1A10 cDNA (GenBank accession number HSU89508).   
The 3’-end of UGT1A10 exon 1 (fragment “2”, size =416 bp) was amplified by PCR  
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using a UGT1A10 exon 1-specific sense primer (1A10S2; 5’-CTCTTTCCTATGTCCCC  
AATG-3’) corresponding to nucleotides 557-577 of the UGT1A10 cDNA and an  
antisense primer (1A10AS2; 5’-CTGGAAAGAAATCTGAAATGCAACAAAC-3’)  
corresponding to nucleotides 54047-54074 of the UGT family 1 loci, which corresponds  
to nucleotides 90-117 downstream of UGT1A10 exon 1 (GenBank accession number  
AF297093).   
PCR amplifications were performed routinely in a 50-µL reaction volume  
containing 50 ng of purified  genomic DNA, 10 mM Tris-HCl (pH 8.3), 50mM KCl, 1.5  
mM MgCl2, 0.2 mM of each of the deoxynucleotide triphosphates, 20 pmol of both sense  
and antisense UGT1A10 primers, and 2.5 units (U) of Taq DNA polymerase (Boehringer  
Mannheim, Indianapolis, IN).  The reaction mixtures for both fragments 1 and 2  
underwent the following incubations in a GeneAmp 9700 Thermocycler (Perkin-Elmer,  
Foster City, CA): 1 cycle of 94 ºC for 2 minutes, 41 cycles of 94 ºC for 30 seconds, 56 ºC  
for 30 seconds, and 72 ºC for 30 seconds, after which a final cycle of 7 minutes at 72 ºC  
was performed.  The PCR amplification integrity of all samples was confirmed by  
electrophoresis in 8% polyacrylamide or 1.5% agarose gels that were stained  
subsequently with ethidium bromide and evaluated under ultraviolet light using a  
computerized photoimaging system (AlphaImager 2000, Alpha Innotech, San Leandro,  
CA). 
For dideoxy sequencing, PCR products were purified after electrophoresis in  
1.5% agarose using the Qiaex II gel extraction kit (Qiagen, Valencia, CA).  Dideoxy  
sequencing was performed at the Molecular Biology Core Facility at the H. Lee Moffitt  
Cancer Center using the same sense and antisense primers that were used for PCR  
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amplification (see procedural flowchart in Figure 14).  
UGT1A10 genotypes for missense polymorphisms were assessed by restriction  
fragment length polymorphism (RFLP) analysis 1) to confirm polymorphic sequences in  
sequenced samples, 2) to screen buccal cell DNA specimens not initially analyzed by  
DNA sequencing for overall polymorphic prevalence, and 3) to screen buccal cells from  
orolaryngeal carcinoma cases and matched controls.  UGT1A10 exon 1 sequences were  
PCR-amplified as described above, and RFLP analysis was performed at 37 ºC for 2  
hours using 10-15 µL of PCR product and 5 U of the appropriate restriction enzyme (EarI  
for UGT1A10 codon 139, BceA I for UGT1A10 codon 240, and EcoR V for UGT1A10  
codon 244; all enzymes were purchased from New England Biolabs, Beverly, MA).   
 
Statistical Analyses 
Statistical analysis included chi-square tests for differences in genotype  
frequencies and the Student t test for continuous variables such as cigarette consumption.   
The risk of orolaryngeal carcinoma in relation to UGT1A10 genotypes was determined  
by conditional logistic regression to calculate odds ratios (OR) and 95% confidence  
intervals (CI).  For all analyses, the regression models included gender, age (continuous),  
pack-years of smoking (continuous), and alcohol consumption (categorical).  The  
statistical computer software SPSS (version 10.1) was used to perform all statistical  
analyses.  All statistical tests were two sided. 
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Buccal Cell Collection 
↓ 
Cell Centrifugation 
↓ 
DNA Isolation and Purification 
↓ 
PCR Amplification  
↓ 
Confirmation of PCR by Electrophoresis 
↓ 
Restriction Fragment Length Polymorphism (RFLP)   
↓ 
Confirmation of Banding by Electrophoresis 
 
 
Figure 14.  Procedural flowchart 
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Results 
Screening for UGT1A10 Polymorphisms 
Although single-nucleotide polymorphism database searches are useful for the  
detection of polymorphisms in unique or non-homologous genes, database searches for  
the identification of polymorphisms in UGT family 1A exon 1 regions are less useful as a  
result of high nucleotide homology with other UGT family 1A members (Owens et al.,  
1995).   
Downstream of this region, six polymorphisms were detected by sequencing  
analysis (Table 3).  Three were “silent” (codons 42, 199, and 231) and three were  
missense polymorphisms resulting in amino acid changes within the UGT1A10 sequence  
(codons 139, 240, and 244; Figure 15).  The codon 139 (G > A) polymorphism resulted  
in a glutamic acid-to-lysine (Glu > Lys) amino acid change, the codon 240 (C > T)  
polymorphism resulted in a threonine-to-methionine (Thr > Met) amino acid change, and  
the codon 244 (C > A) polymorphism resulted in a leucine-to-isoleucine (Leu > Ile)  
amino acid change, as detected by direct sequencing in two (both black), one (white), and  
five (one white, four black) individuals, respectively.  All three amino acid-changing  
polymorphisms were confirmed by RFLP analysis (Figure 16). 
 
Prevalence of UGT1A10 Missense Polymorphisms 
To assess the prevalence of UGT1A10-specific missense polymorphisms in  
different racial/ethnic groups, RFLP analysis was used to screen each of the missense  
polymorphisms in healthy white, African American, and Asian individuals recruited from  
Tampa or New York City (Table 3).  The codon 240 (Thr > Met) polymorphism was  
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Description and Prevalence of UGT1A10 Polymorphisms by Racial Group 
Allelic Prevalence   
African Americansa Whitesb Asiansc 
Codon Nucleotide 
Substitution  
Amino acid  
Substitution
NY FL Total NY FL Total East 
Asian 
Indian 
42 CAG to 
CAA 
No 0.02 Not 
Done
- 0.02 Not 
Done 
- Not 
Done 
Not 
Done 
139 GAG to 
AAG 
Glu to Lys 0.05 0.03 0.04de Not 
detected 
Not 
detected
<0.01 Not 
detected
Not 
detected
199 CAT to 
CAC 
No 0.04 Not 
Done
- 0.02 Not 
Done 
- Not 
Done 
Not 
Done 
231 GCC to 
GCT 
No 0.12 Not 
Done
- 0.14 Not 
Done 
- Not 
Done 
Not 
Done 
240 ACG to 
ATG 
Thr to Met Not 
detected
0.01 <0.01 <0.01 <0.01 <0.01 Not 
detected
Not 
detected
244 CTC to 
ATC 
Leu to Ile 0.04 0.06 0.05fg <0.01 <0.01 <0.01 Not 
detected
Not 
detected
a Prevalence analysis was performed by direct sequencing and/or polymerase chain reaction-restriction fragment length 
polymorphism analysis for 189 black subjects recruited from Mt. Vernon, NY (n = 110), and Tampa, FL (n = 79). 
  b Prevalence analysis was performed by direct sequencing and/or PCR-RFLP analysis for 362 white subjects recruited from 
Mt. Vernon, NY (n = 162), and Tampa, FL (n = 200). 
  c The total number of Asian subjects examined included 35 Indian Asians and 34 subjects of East Asian descent. 
  d Includes 11 subjects who were heterozygous and 2 subjects who were homozygous for the UGT1A10139Lys variant. 
  e Prevalence was significantly greater (P < 0.005 
  f P < 0.001, respectively) in African Americans compared with whites. 
  g All subjects with a UGT1A10244Ile variant were heterozygous. 
Table 3.  Description and prevalence of UGT1A10 polymorphisms by Racial Group                                                                  
(allelic prevalence is defined as the proportion of a specific allele in a population)
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Codon 244 
                     
 
Figure 15.  UGT1A10 polymorphisms identified by sequencing analysis          
(homozygous is defined as containing two copies of the same allele; heterozygous is 
defined as containing two different alleles of the same gene) 
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wild-type 
Homozygous 
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Homozygous 
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Homozygous 
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Codon 139 
 
 
Codon 240 
 
 
Codon 244 
 
 
Figure 16.  RFLP Analysis for codon 139 (EarI digestion), codon 240 (BceAI digestion) 
and codon 244 (EcorV digestion)                                                                      
(WT: WildType; Het: Heterozygote; and Poly: Polymorphic) 
 
         DNA marker    uncut      WT       WT       Het.       Poly.
     DNA marker     uncut     WT       WT       Het.      Het.         
  DNA marker     uncut     WT       WT       Het.      Het.          
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detected in 3 African Americans and 6 whites, with a resulting allelic prevalence of less  
than 0.01 in both groups.  Although the prevalence of both the codon 139 (Glu > Lys)  
and codon 244 (Leu > Ile) polymorphisms was less than 0.01 in whites, the prevalence of  
both polymorphisms wassignificantly higher (P < 0.001 for both polymorphisms) in  
African Americans.  The prevalence of the UGT1A10139Lys-and UGT1A10244Ile-containing  
alleles was 0.04 and 0.05, respectively, in the African American cohort screened in the  
current study.  Although some variation in prevalence was observed for he UGT1A10  
codon 139 and 244 polymorphisms for African Americans recruited from Florida versus  
New York, these differences were not significant.  None of the missense polymorphisms  
were observed in any of the Indian or East Asian individuals screened in the current study  
(same Table 3). 
 
Analysis of UGT1A10 Polymorphisms and Orolaryngeal Carcinoma Risk 
The potential role for UGT1A10 polymorphisms in the risk for orolaryngeal  
carcinoma was evaluated in a case-control study of 115 African American patients with  
newly diagnosed orolaryngeal carcinoma and 115 matched controls.  Seventy-two  
percent of cases and 62% of controls were men.  The mean age for the cases and controls  
was 58 years.  As expected, the average pack-years of smoking was significantly higher  
in case patients than in control patients (39 vs. 9 pack-years, respectively, P < 0.01).   
Only 5% of case patients were never-smokers, compared with 59% of control patients.  A  
higher percentage of case patients than control patients were heavy drinkers of alcohol  
(28 or more shots per week; 49% vs. 16%, P < 0.01). 
Informative PCR results were obtained for all 115 case-control pairs (230 total  
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UGT1A10 Genotype Prevalence and Risk for Orolaryngeal Carcinoma 
UGT1A10 
genotype 
Controls       
(%) 
Cases           
(%) 
Crude OR 
(95% CI) 
Adjusted OR 
(95% CI)a 
Codon 139b  
Glu > Glu 99 (86) 108 (95.6) 1.0 (referent) 1.0 (referent) 
Glu > Lysc 16 (14) 5 (4.4) 0.29          
(0.10-0.81) 
0.20          
(0.05-0.87) 
Codon 244d  
Leu > Leu 101 (91) 105 (91.3) 1.0 (referent) 1.0 (referent) 
Leu > Ilec 10 (9.0) 10 (8.7) 0.96          
(0.38-2.40) 
0.94          
(0.26-3.40) 
OR, odds ratio; CI, confidence interval. 
  a Adjusted for age, gender, smoking (pack-years), and alcohol consumption (categoric 
variables). 
  b Noninformative polymerase chain reaction analyses were obtained in two cases for 
codon 139 analysis. 
  c None of the subjects screened in the case-control study were homozygous for the 
polymorphic variant for either the UGT1A10 codon 139 or 244 polymorphism. 
  d Noninformative Polymerase chain reaction analyses were obtained in four controls for 
codon 244 analysis. 
 
Table 4.  UGT1A10 genotype prevalence and risk for orolaryngeal carcinoma 
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subjects) except for the UGT1A10 codon 139 polymorphism in 2 case patients and the  
UGT1A10 codon 244 polymorphism in 4 control patients (Table 4).  Among control  
patients, the prevalence of these polymorphisms followed the Hardy-Weinberg  
equilibrium and the prevalence of both polymorphisms was similar to that observed for  
African Americans in New York (Table 4).  There was no significant difference in allelic  
prevalence between men and women among either case patients or control patients. 
There was no significant difference (p > 0.05) in the prevalence of the  
UGT1A10244Ile polymorphic variant between case patients (allelic prevalence, 0.043) and  
control patients (allelic prevalence, 0.045).  A significantly (p < 0.01) higher prevalence  
of the UGT1A10139Lys polymorphic variant was observed in control patients (allelic  
prevalence, 0.07) than in case patients (allelic prevalence, 0.022).  As shown in Table 4,  
individuals with 1 or more UGT1A10139Lys polymorphic variants exhibited a significant  
decrease in risk for orolaryngeal carcinoma (ORcrude, 0.29; 95% CI, 0.10-0.81; P < 0.02).   
This risk was not affected by adjusting for other factors via regression analysis (ORadjusted,  
0.20; 95% CI, 0.05-0.87).  There was no association between the UGT1A10244Ile  
polymorphic variant and orolaryngeal carcinoma risk (ORadjusted, 0.94; 95% CI, 0.26-3.4). 
 
Discussion 
UGT1A10 has been implicated strongly in the glucuronidation of several  
important BaP metabolites including BaP-7,8-dihydrodiol, the precursor to the potent  
mutagen, BaP-7,8-dihydrodiol-9,10-epoxide (Fang et al., 2002).  Although most family  
1A UGTs are expressed in the liver, UGT1A10 is extrahepatic (Strassburg et al., 1999)  
and is expressed in several target areas (Strassburg et al., 1998; Strassburg et al., 1998;  
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Strassburg et al., 2000) for tobacco-induced malignancies, including the oral cavity and  
the larynx (Zheng et al., 2002).  Therefore, UGT1A10 may play an important role in the  
detoxification of tobacco-smoke carcinogens, such as BaP, in these tissues. 
Previous studies have shown that few UGT family 1A missense polymorphisms  
have been identified in the exon 2-5 common region of the family 1A locus (Huang et al.,  
2000).  In the current study, several polymorphisms were identified in the UGT1A10- 
specific region (UGT1A10 exon 1).  Of these, three resulted in amino acid changes that  
could potentially alter UGT1A10 protein function.  The prevalence of all 3 missense  
polymorphisms was less than 1% in whites, and none of these polymorphisms were  
identified in a small cohort of Asian individuals.  These data suggest that coding region  
variations in UGT1A10 are rare and do not play a significant role in cancer susceptibility  
in these ethnic groups.  Due to their low prevalence, it was not possible to determine the  
risk of orolaryngeal carcinoma associated with UGT1A10 polymorphisms in these  
groups. 
A significantly decreased risk of orolaryngeal carcinoma was found to be  
associated with the UGT1A10 codon 139 (Glu > Lys) polymorphism but not with the  
codon 244 (Leu > Ile) polymorphism in African Americans.  These data are consistent  
with the finding that the amino acid change from Glu > Lys for the codon 139  
polymorphism is a highly nonconservative change in amino acid sequence and is  
therefore a more likely candidate to alter UGT1A10 function than the Leu > Ile change  
observed for the codon 244 polymorphism.   
The protective effect of the UGT1A10139Lys variant on orolaryngeal carcinoma risk  
observed in the current study would suggest that this variant may exhibit higher   
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glucuronidating and, therefore, detoxifying activity against tobacco carcinogens like BaP- 
7,8-dihydrodiol.  Alternatively, the codon 139 polymorphism may be in linkage  
disequilibrium with another marker in the UGT1 locus.   
The current study has two potential limitations.  The overall study sample was  
relatively small, which limited our ability to determine gene-environment interactions.   
There were only six case participants who never smoked cigarettes, and consequently it  
was not possible to determine gene-smoking interactions.  It should be emphasized that  
despite this limitation, this is the largest molecular epidemiologic case-control study of  
orolaryngeal carcinoma risk yet performed in African Americans. 
Another potential limitation of the current study is that the control patients  
recruited into the study were hospital outpatients attending dental or ear, nose, and throat  
clinics.  It could be proposed that they may not reflect the overall prevalence of  
UGT1A10 alleles in the general population.  However, as part of the International Project  
on Genetic Susceptibility to Environmental Carcinogens database, a large pooled analysis  
of more than 15,000 individuals without cancer was performed and no statistically  
significant differences in the overall prevalence of metabolizing enzyme polymorphisms  
between hospital-based and population-based controls were found (Garte et al., 2002).  In  
addition, in contrast with the relatively poor response rates of most studies that use  
‘population’-based controls, the response rate of control patients in the current study was  
very high (> 95%), thus limiting potential representation biases introduced by selective  
control recruitment.  Therefore, although not proven, it is unlikely that the use of  
hospital-based outpatient controls substantially biased the findings of the current study. 
In conclusion, polymorphisms in the UGT1A10 gene were detected and, of these,  
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the codon 139 polymorphism may be an important risk factor for orolaryngeal carcinoma  
in African Americans.  Functional studies of UGT1A10 polymorphic variants as well as  
studies determining UGT1A10 expression levels in various human tissue specimens will  
be necessary to better characterize the effects of UGT1A10 polymorphisms on patient risk  
for other malignancies.   
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CHAPTER TWO 
UGT1A9 AND UGT2B7 POLYMORPHISMS: IDENTIFICATION AND 
PREVALENCE IN DIFFERENT RACIAL GROUPS 
Abstract 
Exposure to polycyclic aromatic hydrocarbons (PAHs) such as benzo(a)pyrene  
are important risk factors for colon cancer.  Two UDP-glucuronosyltransferases,  
UGT1A9 and UGT2B7, have been shown to play an important role in the phase II  
metabolism of procarcinogenic metabolites of BaP.  Because both enzymes are well- 
expressed in digestive tract tissues including colon, it is possible that genetic variations in  
either enzyme may play an important role in colon cancer risk.  This study examined  
UGT1A9- and UGT2B7-specific sequences for polymorphisms that potentially play a role  
in cancer susceptibility.  The UGT1A9 gene was analyzed by direct sequencing of  
genomic DNA isolated from buccal cell swabs from 90 healthy subjects (43 African  
Americans and 47 Caucasians).  One silent polymorphism and two missense  
polymorphisms at codons 167 (Val>Ala) and 183 (Cys>Gly) were identified.  The  
UGT2B7 gene was analyzed by direct sequencing of genomic DNA (exon 1) and RNA  
(exon 2-6) extracted from 39 normal liver specimens from individual subjects.  In  
addition to seven silent polymorphisms, one previously-reported missense polymorphism  
was identified.  The prevalence of each missense polymorphism was determined by  
PCR-RFLP analysis of buccal cell DNA from an additional 206 Caucasians, 121 African  
Americans, and 59 Asians for UGT1A9, and an additional 225 Caucasians, 128 African  
Americans, and 57 Asians for UGT2B7.  The combined prevalence (sequencing + RFLP)  
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of the UGT1A9167Ala and UGT1A9183Gly variant alleles was 0.004 and 0.025, respectively,  
for Caucasians, and 0.003 and 0.01, respectively, for African Americans.  None of the  
missense UGT1A9 variant alleles were found in any of the Asian subjects.  The  
combined prevalence (sequencing + RFLP) of the UGT2B7268Tyr variant was 0.44 for  
Caucasians, 0.25 for African Americans, and 0.28 for Asians.  These data suggest that the  
UGT2B7 His268Tyr and UGT1A9 Cys183Gly polymorphisms may be important  
variables in risk for colon cancer. 
 
Materials and Methods 
 
Tissues and Study Population for UGT2B7 and UGT1A9 
For screening the UGT2B7 gene for polymorphisms, matching genomic DNA and  
total RNA, purified from normal liver specimens, were provided by the Tissue  
Procurement Facility at the H. Lee Moffitt Cancer Center from individuals (n = 39)  
undergoing surgery for resection of hepatocellular carcinoma; the tissues were quick- 
frozen at –70 ºC within 2 hours post-surgery.  All subjects were Caucasian, 44% were  
female, and the average age of these subjects was 64 years.  All protocols involving the  
analysis of tissue specimens were approved by the institutional review board at the  
University of South Florida (USF) and collaborating institutions, and in accordance with  
assurances filed with and approved by the United States Department of Health and  
Human Services. 
For the determination of UGT2B7 polymorphic prevalence in different racial  
groups, our population included 225 whites, 128 African Americans, and 57 Asians.   
Healthy, cancer-free Caucasian and African American subjects were recruited at the  
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Lifetime Cancer Screening Center at the H. Lee Moffitt Cancer Center, and Asian  
subjects were employed at H. Lee Moffitt Cancer Center/USF. 
For screening the UGT1A9 gene for polymorphisms, genomic DNA was isolated  
from buccal cell swabs from 90 healthy subjects (43 African Americans and 47  
Caucasians).  DNA was isolated from exfoliated buccal cell specimens by incubating cell  
pellets with proteinase K (0.1 mg/mL) in 1% sodium dodecyl sulfate overnight at 50 °C,  
extracting with phenol:chloroform, and precipitating with ethanol as previously  
described.  Care was taken during DNA purification and isolation to prevent  
contamination and cross-contamination between samples during polymerase chain  
reaction (PCR).  The purification of DNA samples was performed in a location distant  
from the workstation where PCR amplifications were performed.  All equipment used for  
tissue blending and homogenization was washed in a bath of concentrated chromic  
acid/sulfuric acid, rinsed 3 times in autoclaved double-distilled water and once in 70%  
ethanol, air-dried, and autoclaved after each tissue sample was processed as described  
above. 
For the determination of UGT1A9 polymorphic prevalence in different racial  
groups, our population included 206 whites, 121 African Americans, and 59 Asians.   
Healthy, cancer-free Caucasian and African American subjects were recruited at the  
Lifetime Cancer Screening Center at the H. Lee Moffitt Cancer Center, and Asian  
subjects were employed at H. Lee Moffitt Cancer Center/USF.  
All these subjects were participants previously recruited for studies of genetic  
polymorphisms and other factors in risk for aerodigestive tract cancer (Elahi et al., 2002;  
Park et al., 2000; Richie et al., 1997).    
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PCR Amplifications, Sequencing and Genotyping Analysis  
 
For screening of the UGT2B7 coding region for polymorphisms, a dual PCR  
amplification strategy was employed.  The goal of this approach was to sequence all six  
exons of UGT2B7 with minimal effort but with high gene specificity.  Exon 1-encoded  
sequences, which comprise nearly one-half the UGT2B7 cDNA, were individually PCR- 
amplified using genomic DNA (purified from normal liver as described above) as  
template, while UGT2B7 exons 2-6 were PCR-amplified after single-strand cDNA  
synthesis of total RNA (purified from the same liver specimens used for genomic DNA- 
PCR amplifications).  The primers used for UGT2B7 exon 1 PCR-amplification were  
2B7E1S (sense; 5’-TTAACTTCTTGGCTAATTTATCTTTGGACA-3’) corresponding  
to nucleotides –91 through –61 relative to the translation start site in UGT2B7 exon 1  
(GenBank accession number NT-030640), and 2B7E1A (antisense; 5’ATCCCACTTCTT 
CATGTCAAATATTTC-3’) corresponding to nucleotides +673 through +699 relative to  
the UGT2B7 exon 1/intron 1 splice junction, resulting in a PCR amplimer of 721 bp.   
UGT2B7 exons 2-6 were amplified by RT-PCR using primers 2B7E2S (sense; 5’- 
CTATGTGCTTTACTTTGACTTTTGGTTCG-3’) corresponding to nucleotides +645  
through +673 of the UGT2B7 cDNA (GenBank accession number BC030974), and  
2B7E2A (antisense; 5’-CCAGCTTCAAATCTCAGATATAACTAATCAT-3’)  
corresponding to UGT2B7 cDNA nucleotides +1583 through +1613, resulting in a PCR  
amplimer of 870 bp.   
PCR amplifications of UGT2B7 exon 1 sequences were routinely performed in a  
50 µL reaction volume containing 50 ng of purified DNA, 10 mM Tris-HCl (pH 8.3), 50  
mM KCl, 1.5 mM MgCl2, 0.2 mM of each of deoxynucleotide trisphosphates, 20 pmole  
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of both sense and antisense UGT2B7 primers, and 2.5 units of Taq DNA polymerase.   
Incubations were performed in a GenAmp 9700 Thermocycler (Perkin-Elmer Corp.,  
Foster City, CA) as follows: 1 cycle of 94 ºC for 2 min, 41 cycles of 94 ºC for 30 sec, 55  
ºC for 30 sec, and 72 ºC for 30 sec, followed by a final cycle of 7 min at 72 ºC.   
The amplification of UGT2B7 exons 2-6 was performed after an initial RT  
reaction using 3 µg of total RNA and 200 units of reverse transcriptase in a 50 min  
incubation at 42 ºC, followed by PCR as described above for exon 1 sequences but using  
5 µL of the RT reaction at an annealing temperature of 60 ºC.  The integrity of all  
samples was confirmed by electrophoresis in 8% polyacrylamide or 1.5% agarose gels  
that were subsequently stained with ethidium bromide and examined over UV-light using  
a computerized photoimaging system (AlphaImagerTM 2000, Alpha Innotech Corp., San  
Leandro, CA). 
For dideoxy sequencing, PCR products were purified after electrophoresis in  
1.5% agarose using the QIAEX® II gel extraction kit (Qiagen, Valencia, CA).  Dideoxy  
sequencing was performed at the Department of Genetics/DNA Sequencing Facility at  
the Children’s Hospital at the University of Pennsylvania Medical Center using the same  
sense and antisense primers as were used for UGT2B7 amplifications. 
UGT2B7 genotypes for missense polymorphisms were assessed by restriction  
fragment length polymorphism (RFLP) analysis after PCR amplification using primers  
2B7S (sense; 5’-TGCCTACACTATTCTAACC-3’) corresponding to nucleotides +1994  
through +2012 relative to the UGT2B7 exon 1/intron 1 splice junction (GenBank  
accession number NT-030640), and 2B7A (antisense; 5’-AGTGCAGAATTTTCAGAGA 
-3’) corresponding to nucleotides +2555 through +2573 relative to exon 2/intron 2 splice  
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junction (GenBank accession number NT-030640), using an annealing temperature of 58  
ºC to produce a PCR-amplified product of 580 bp.   
RFLP analysis was performed at 37 ºC for 2 hours using 10-15 µL of PCR  
product and 0.1 units of the FokI restriction enzyme.  Digestions were electrophoresed on  
8% PAGE gels that were subsequently stained with ethidium bromide and examined over  
UV-light.  
The family 1A locus comprises divergent and individually regulated exon 1  
sequences that transcribe for mRNAs that are spliced alternatively onto the 5’-end of the  
sequence encoded by the common UGT exon 2-5 region.  Therefore, UGT mRNAs  
consist of a unique region encoded by exon 1 and a region encoded by exons 2-5 that is  
common for all family 1A UGTs.  To evaluate sequences that were UGT1A9 specific and  
that spanned the entire UGT1A9 exon 1 region, PCR amplification strategy was  
employed.  Exon 1-encoded sequences were individually PCR-amplified using genomic  
DNA (isolated from buccal cells as described above).  The primers used for UGT1A9  
exon 1 PCR-amplification were 1A9E1S (sense; 5’-CGCCCTCTATTGGGGTCAG-3’)  
corresponding to nucleotides –100 through –82 relative to the translation start site in  
UGT1A9 exon 1 (GenBank accession number AF297091), and 1A9E1A (antisense; 5’- 
AATTTCCAAAGGTGAAGTATTCTT-3’) corresponding to nucleotides +882  
through +905 relative to the UGT1A9 exon 1/intro 1 splice junction, resulting in a PCR  
amplimer of 1005 bp.   
PCR amplifications of UGT1A9 exon 1 sequences were performed in a 50 µL  
reaction volume containing 50 ng of purified DNA, 10 mM Tris-HCl (pH 8.3), 50 mM  
KCl, 1.5 mM MgCl2, 0.2 mM of each of deoxynucleotide trisphosphates, 20 pmole of  
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both sense and antisense UGT1A9 primers, and 2.5 units of Taq DNA polymerase.   
Incubations were performed in a GenAmp 9700 Thermocycler (Perkin-Elmer Corp.,  
Foster City, CA) as follows: 1 cycle of 94 ºC for 5 min, 40 cycles of 94 ºC for 30 sec, 60  
ºC for 30 sec, and 72 ºC for 1 min, followed by a final cycle of 7 min at 72 ºC.  The  
integrity of all samples was confirmed by electrophoresis in 8% polyacrylamide or 1.5%  
agarose gels that were subsequently stained with ethidium bromide and examined over  
UV-light using a computerized photoimaging system (AlphaImagerTM 2000, Alpha  
Innotech Corp., San Leandro, CA). 
For dideoxy sequencing, PCR products were purified after electrophoresis in  
1.5% agarose using the QIAEX® II gel extraction kit (Qiagen, Valencia, CA).  Dideoxy  
sequencing was performed at the Department of Genetics/DNA Sequencing Facility at  
the Children’s Hospital at the University of Pennsylvania Medical Center using the same  
sense and antisense primers as were used for UGT1A9 amplifications. 
UGT1A9 exon 1 sequences were PCR-amplified as described above, and RFLP  
analysis was performed at 37 ºC for 2 hours using 10-15 µL of PCR product and 5 U of  
the appropriate restriction enzyme (BbsI for UGT1A9 codon 167 and NiaIV for UGT1A9  
codon 183; all enzymes were purchased from New England Biolabs, Beverly, MA).   
Digestions were electrophoresed on 8% PAGE gels that were subsequently stained with  
ethidium bromide and examined over UV-light (see procedural flowchart in Figure 17). 
 
Results 
 
Screening for UGT2B7 and UGT1A9 Polymorphisms 
Eight polymorphisms were detected by sequencing analysis for UGT2B7 (Table  
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Buccal Cell Collection 
↓ 
Cell Centrifugation 
↓ 
DNA Isolation and Purification 
↓ 
PCR Amplification  
↓ 
Confirmation of PCR by Electrophoresis 
↓ 
Restriction Fragment Length Polymorphism (RFLP)   
↓ 
Confirmation of Banding by Electrophoresis 
 
Figure 17.  Procedural flowchart 
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UGT1A9 and UGT2B7 Silent Polymorphisms 
UGT Location Nucleotide substitution 
1A9 Codon 66 CTG to TTG 
   
2B7 Codon 124 AGA to AGG 
Codon 245 ACG to ACA 
Codon 246 TTA to TTC 
Codon 267 CCT to CCA 
Codon 285 GCC to GCA 
Codon 353 CTG to CTC 
 
Codon 354 TAT to TAC 
 
UGT1A9 and UGT2B7 Missense Polymorphisms 
UGT Location Nucleotide        
substitution 
Amino acid      
substitution 
1A9 Codon 167 GTC to GCC Val to Ala 
 Codon 183 TGC to GGC Cys to Gly 
    
2B7 Codon 268 CAT to TAT His to Tyr 
 
Table 5.  UGT1A9 and UGT2B7 polymorphisms 
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5).  Seven of them were “silent” (codons 124, 245, 246, 267, 285, 353, and 354) and one  
previously-reported missense polymorphism (Holthe et al., 2003) resulting in an amino  
acid change within the UGT2B7 sequence (codon 268; Figure 18).  The codon 268 (CAT 
> TAT) polymorphism resulted in a histidine-to-tyrosine (His > Tyr) amino acid change  
which was confirmed by RFLP analysis (Figure 19).   
Three polymorphisms were detected by sequencing analysis for UGT1A9 (Table  
5).  One was “silent” (codon 66) and two were missense polymorphisms resulting in  
amino acid changes within the UGT1A9 sequence (codons 167 and 183; Figure 20).  The  
codon 167 (GTC > GCC) polymorphism resulted in a valine-to-alanine (Val > Ala)  
amino acid change and the codon 183 (TGC > GGC) polymorphism resulted in a  
cysteine-to-glycine (Cys > Gly) amino acid change.  Both amino acid-changing  
polymorphisms were confirmed by RFLP analysis (Figure 21). 
 
Prevalence of UGT2B7 and UGT1A9 Missense Polymorphisms 
To assess the prevalence of UGT2B7-specific missense polymorphism in different  
racial/ethnic groups, RFLP analysis was used to screen the missense polymorphism in  
healthy white, African American, and Asian individuals recruited from Tampa or New 
York City (Table 6).  The combined prevalence (sequencing + RFLP) of the  
UGT2B7268Tyr variant was 0.44 for Caucasians, 0.25 for African Americans, and 0.28 for  
Asians. 
To assess the prevalence of UGT1A9-specific missense polymorphisms in  
different racial/ethnic groups, RFLP analysis was used to screen the missense  
polymorphisms in healthy white, African American, and Asian individuals recruited  
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Homozygous Wild-Type                    Heterozygote                   Homozygous Polymorphic 
 
Figure 18.  UGT2B7 polymorphism (Codon 268) identified by sequencing analysis 
(homozygous is defined as containing two copies of the same allele; heterozygous is 
defined as containing two different alleles of the same gene) 
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Codon 268 
       
                         
 
Figure 19.  RFLP Analysis for codon 268 (FokI digestion)                                            
(WT: WildType; Het :Heterozygote; and Poly: Polymorphic) 
 
 
 
 
 
 
 
 
 
711 bp → 
489 bp → 
328 bp → 
147 bp → 
DNA marker        uncut            Het.              WT             Het.              Het.              Poly.      
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Codon 167 
                           
                        Homozygous Wild-Type                          Heterozygote 
 
Codon 183 
                           
Homozygous Wild-Type                          Heterozygote 
 
Figure 20.  UGT1A9 polymorphisms identified by sequencing analysis             
(homozygous is defined as containing two copies of the same allele; heterozygous is 
defined as containing two different alleles of the same gene) 
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Codon 167 
 
 
 
 
Codon 183 
 
 
 
Figure 21.  RFLP Analysis for codon 167 (BbsI digestion) and for codon 183 (NiaIV 
digestion)                                                                                         
(WT: WildType and Het: Heterozygote) 
 
 
DNA marker       uncut           Het.            WT
711 bp → 
489 bp → 
328 bp → 
DNA marker         WT     WT     WT     Het.
711 bp → 
489 bp → 
328 bp → 
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UGT1A9 and UGT2B7 missense polymorphisms and allelic prevalence 
 Allelic Prevalence 
 Codon Nucleotide   
Substitution
Amino 
Acid   
Substitution
African 
Americans
Whites Asians 
UGT1A9 167 GTC to 
GCC 
Val  to   
Ala 
0.003 0.004 Not 
detected 
 183 TGC to 
GGC 
Cys to   Gly 0.01 0.025 Not 
detected 
UGT2B7 268 CAT to 
TAT 
His to    
Tyr 
0.25 0.44 0.28 
 
Table 6.  UGT1A9 and UGT2B7 missense polymorphisms and allelic prevalence   
(allelic prevalence is defined as the proportion of a specific allele in a population) 
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from Tampa or New York City (Table 6).  The combined prevalence (sequencing +  
RFLP) of the UGT1A9167Ala and UGT1A9183Gly variant alleles was 0.004 and 0.025,  
respectively, for Caucasians, and 0.003 and 0.01, respectively, for African Americans.   
None of the missense UGT1A9 variant alleles were found in any of the Asian subjects. 
 
Discussion 
Previous studies have shown that few UGT family 1A missense polymorphisms  
have been identified in the exon 2-5 common region of the family 1A locus (Huang et al.,  
2000).  In the current study, three new polymorphisms were identified by sequencing  
analysis in the UGT1A9-specific region (UGT1A9 exon 1).  Of these, two resulted in  
amino acid changes that could potentially alter UGT1A9 protein function.  The codon  
167 (GTC > GCC) and the codon 183 (TGC > GGC) polymorphisms resulted in a valine  
to alanine and cysteine to glycine amino acid changes, respectively.  The combined  
prevalence (sequencing + RFLP) of the 167ala and 183gly variant alleles were 0.004 and  
0.025, respectively, for Caucasians and 0.003 and 0.01, respectively, for African  
Americans. The prevalence of both missense polymorphisms was less than 1% in African  
Americans, and none of these polymorphisms were identified in a small cohort of Asian  
individuals.  Therefore, these data suggest that coding region variations in UGT1A9 are  
rare and do not play a significant role in cancer susceptibility in these ethnic groups.   
In addition, eight new polymorphisms were identified by sequencing analysis in  
the UGT2B7 gene.  Of these, only 1 previously identified missense polymorphism  
resulted in an amino acid change that could potentially alter UGT2B7 protein function.   
The codon 268 (CAT > TAT) polymorphism resulted in a histidine to tyrosine amino  
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acid change.  The prevalence of the 268tyr variant allele was 0.44 for Caucasians, 0.25  
for African Americans and 0.28 for Asians. 
In conclusion, Polymorphisms identified in the UGT1A9 gene and UGT2B7 gene  
resulted in amino acid changes that may potentially alter UGT1A9 and UGT2B7 protein  
function.  Therefore, the codon 183 (Cys > Gly) polymorphism of UGT1A9 and the  
codon 268 (His > Tyr) polymorphism of UGT2B7 could play a role in cancer risk. 
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CHAPTER THREE 
 
FUNCTIONAL CHARACTERIZATION OF THE UGT1A9183Gly POLYMORPHIC 
VARIANT 
 
Abstract 
UGT1A9 is a human UDP-glucuronosyltransferase (UGT) shown to play an  
important role in the phase II metabolism of procarcinogenic metabolites of  
benzo(a)pyrene (BaP) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), as  
well as colon carcinogens like 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5- 
b]pyridine (Phip).  As UGT1A9 is expressed in liver as well as in tissues of the digestive  
tract including colon and esophagus, these enzymes may play an important role as  
detoxifiers of digestive tract carcinogens.  A prevalent missense polymorphism has been  
previously identified at codon 183 of the UGT1A9 gene.  To determine whether this  
change in amino acid sequence results in aberrant UGT1A9 enzyme activity, functional  
characterization of the wild-type- and variant-encoded UGT1A9 isoforms was performed  
in vitro after cloning and stable transfection of wild-type and variant UGT alleles into the  
non-UGT-expressing HK293 cell line.  Cell homogenates were prepared from UGT1A9- 
transfected cells and glucuronidation assays were performed using equal amount of total  
cell protein against various carcinogens/carcinogen metabolites including B[a]P-7,8-diol  
and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), as well as other phenolic  
and steroidal compounds including 1-hydroxy (OH)-pyrene, 3-OH-BaP, 7-OH-BaP, and  
9-OH-BaP.  Levels of UGT enzyme activity were determined in three separate  
experiments by HPLC analysis and calculated both before and after normalization for cell  
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homogenate of UGT1A9 protein levels as determined  by Western blot analysis.  A  
significant (p < 0.001) 3- to 4-fold decrease in activity was observed for the  
UGT1A9183Gly variant as compared to its wild-type counterpart for all substrates  
analyzed.  Although high levels of activity were observed for the wild-type  
UGT1A9183Cys variant against NNAL, none was detected in assays with the  
UGT1A9183Gly variant.  Significant (p < 0.05) decreases in UGT1A9 activity were  
observed prior to UGT protein normalization in assays using 9- OH-BaP or BaP-7,8- 
diolas substrate.  These results demonstrate that the UGT1A9 (Cys183Gly) polymorphism  
significantly alters UGT1A9 function and could potentially play an important role as risk  
modifier for digestive tract cancers. 
 
Materials and Methods 
 
Chemicals and Materials 
3-OH-BaP, 7-OH-BaP, 9-OH-BaP, and BaP-7,8-dihydrodiol were obtained from  
the National Cancer Institute Chemical Carcinogen Repository (synthesized and  
characterized at Midwest Research Institute, Kansas City, MO), while NNAL was  
obtained from Toronto Chemicals (Toronto, Canada).  UDPGA, D,L-2-lysophosphatidyl  
choline palmital C16:0, and 1-OH-pyrene were purchased from Sigma (St. Louis, MO).   
14C-UDPGA (specific activity: 300 mCi/mmol) was obtained from American  
Radiolabeled Chemicals (St. Louis, MO).  Dulbecco’s modified Eagle’s medium was  
obtained from Mediatech (Herndon, VA) and both fetal bovine serum and geneticin  
(G418) were purchased from Life Technologies (Grand Island, NY). Taq DNA  
polymerase (HotMaster) was purchased from Perkin Elmer Biosystems (Foster City,  
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CA), and the human UGT1A9 western blotting kit was purchased from Gentest (Woburn,  
MA).  HPLC-grade solvents were provided by various suppliers and used after filtration.   
All other chemicals were of analytical grade and used without further purification. 
 
RT-PCR Analysis 
Total RNA was isolated from 108 UGT1A9-overexpressing cells by using the  
guanidinium isothiocyanate/cesium chloride method and treatment with Dnase I.  Total  
RNA specimens were stored at –70 °C in individual aliquots.  RT (Reverse  
Transcriptase) was performed in 20 µL volumes using 3 µg total RNA, 200 units  
Superscript II reverse transcriptase (GIBCO/BRL, Gaithersburg, MD), and 0.5 µg of  
oligo (dT)16 primer as outlined in the manufacturer’s protocol.   
For PCR (50 µL final volume), each reaction was performed using 5 µL of RT  
reaction, 0.2 mM dNTPs, 5 units Taq DNA polymerase (Boehringer Mannheim), and 20  
pmole of sense (5’-AGTTCTCTGATGGCTTGC-3’) and antisense (5’-TTTTACCTTA 
TTTCCCACCC-3’) UGT1A9-specific primers.  Reactions were incubated in a Perkin- 
Elmer 9600 Thermocycler (Perkin-Elmer Corp., Foster City, CA) for 1 cycle of 94 °C for  
5 min, 40 cycles of 94 °C for 30 sec, 55 °C for 45 sec, and 72 °C for 1 min, followed by 1  
cycle at 72 °C for 7 min.   
Polyacrylamide gel (1.5%) electrophoresis was performed for the RT-PCR (10 µL  
aliquot) reaction, and analysis and quantification of ethidium bromide-stained products  
performed using a computerized photoimager system (AlphaImagerTM 2000, Alpha  
Innotech Corp. San Leandro, CA).  Representative RT-PCR products were purified after  
electrophoresis in 1.5% agarose using the QIAEX® II gel extraction kit (Qiagen,  
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Valencia, CA), and dideoxy sequencing was performed (Molecular Core Facility, H. Lee  
Moffitt Cancer Center) using the same sense and antisense primers as were used for  
UGT1A9 amplification, to confirm the UGT1A9 wild-type sequence of the RT-PCR  
product. 
 
TOPO® Cloning Reaction, Transformation, and Plasmid DNA Extraction 
The pcDNA3.1/V5-His© TOPO® TA Expression kit provides a highly efficient, 5  
minute, one-step cloning strategy for the direct insertion of Taq polymerase-amplified  
PCR products into a plasmid vector (pcDNA3.1/V5-His-TOPO®; Figure 22).   
The TOPO® cloning reaction (6 µL) was set up using 4 µL of PCR product, 1 µL  
of sterile water, and 1 µL of TOPO® vector.  The reaction was mixed gently and  
incubated for 5 min at room temperature (22-23 °C).  It was then placed on ice to proceed  
to One Shot® Chemical transformation.  2 µL of the TOPO® Cloning reaction from the  
previous step were added into a vial of One Shot® TOP10 Chemically Competent E. coli  
and mixed gently.  The reaction was incubated on ice for 20 min, then heat shocked for  
30 sec at 42 °C, and immediately transferred to ice.  250 µL of room temperature SOC  
medium was added and then the tube was capped and shaken (200 rpm) at 37 ºC for 1  
hour.  100 µL from each transformation was spread on a pre-warmed selective plate  
(ampicillin treated) and incubated overnight at 37 ºC.  Next day, colonies were picked  
from agar plates and added into a round bottom tube containing 2.5 ml of LB media  
treated with ampicillin.  The tubes were put in a shaker overnight to grow at 37 ºC.  
Plasmid DNA extraction was done the following day using QIAprep Spin Plasmid Mini  
kit. 
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Figure 22.  pcDNA3.1/V5-His-TOPO® vector    
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RFLP analysis was performed at 37 ºC for 2 hours using 5 µL of plasmid DNA  
and 5 U of the appropriate restriction enzyme (DraI) to check for right product (insert +  
vector) in the correct orientation; all enzymes were purchased from New England  
Biolabs, Beverly, MA).  Digestions were electrophoresed on 1.5% agarose gels that were  
subsequently stained with ethidium bromide and examined over UV-light. 
Dideoxy sequencing was performed (Molecular Core Facility, H. Lee Moffitt  
Cancer Center) using the T7 and BGH primers provided by the TOPO® Cloning kit, to  
confirm the UGT1A9 wild-type sequence in the pcDNA3.1/V5-His-TOPO® vector. 
 
Site-Directed Mutagenesis 
This method uses a proof-reading polymerase to read all the way around a  
plasmid and thus incorporates the primer as the new (mutant) sequence.  Both of the  
mutagenic oligonucleotide primers were complimentary to each other and contained the  
desired mutation in order to anneal to the same sequence on opposite strands of the  
plasmid (Figure 23).   
PCR amplifications of the plasmid (vector + insert) sequences were routinely  
performed in a 50 µL reaction volume containing 500 ng of plasmid DNA, 50 mM  
MgSO4, 10 mM dNTP mixture, 10X amplification buffer, 20 pmole of both sense (5’- 
CTTGAAGAAGGTGCACAGGGCCCTGCTCCTCTTTCC-3’) and antisense (5’- 
GGAAAGAGGAGCAGGGCCCTGTGCACCTTCTTCAAG-3’) primers, and 2.5 units  
of Platinum® Pfx DNA polymerase.  Incubations were performed in a GenAmp 9700  
thermocycler (Perkin-Elmer Corp., Foster City, CA) as follows: 1 cycle of 95 ºC for 30  
sec and 12 cycles of 95 ºC for 30 sec, 55 ºC for 1 min, and 68 ºC for 15 min.  PCR  
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Figure 23.  Illustration of the basic steps in a site-directed mutagenesis method 
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reaction was cooled to room temperature and 2 units of restriction enzyme DpnI were  
added to cut the methylated DNA (the parental plasmid DNA will be cut to pieces while  
the nascent PCR DNA is left intact).  The reaction was left to incubate at 37 ºC for 1 hour  
followed by transformation into competent E. coli as described above.  Plasmid DNA  
extraction was done the following day using QIAprep Spin Plasmid Mini kit. 
RFLP analysis was performed at 37 ºC for 2 hours using 5 µL of plasmid DNA  
and 5 U of the appropriate restriction enzyme (ApaI) to check for right product (insert +  
vector); all enzymes were purchased from New England Biolabs, Beverly, MA).   
Digestions were electrophoresed on 1.5% agarose gels that were subsequently stained  
with ethidium bromide and examined over UV-light. 
Dideoxy sequencing was performed (Molecular Core Facility, H. Lee Moffitt  
Cancer Center) using the T7 and BGH primers provided by the TOPO® Cloning kit, to  
confirm the UGT1A9 polymorphic sequence in the pcDNA3.1/V5-His-TOPO® vector. 
 
Transfection Using LipofectamineTM 2000, Cell Lines and Cell Homogenate  
 
Preparation 
HK293 (human embryonic kidney fibroblast) cells were kindly provided by Dr.  
Thomas  Tephly (University of Iowa, Iowa City, IA).  The cells were removed from  
liquid nitrogen, defrosted in a large beaker containing water at 37 °C, and immediately  
transferred into cell culture dishes with media prepared earlier (for 500 ml of Modified  
Eagle’s medium, add 5 ml of 100 mM sodium pyruvate solution, 5ml of 100X non- 
essential amino acids solution, 50 ml of fetal bovine serum, and 5 ml of  
penicillin/streptomycin).  The HK293 cells were grown to approximately 80% confluence  
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and then transfected using DNA-Lipofectamine complexes (as described in the  
manufacturer’s protocol, LipofectamineTM 2000, Invitrogen Corp., Carlsbad, CA). 
For stable cell lines, the cells were passed at a 1:20 dilution into fresh growth  
medium 24 hours after transfection.  Selective medium was prepared earlier using 500 ml  
of Dulbecco’s Modified Eagle’s medium supplemented with 4.5 mM glucose, 10 mM  
HEPES, 10% fetal bovine serum, 100 U/ml penicillin, 100 µg streptomycin, and 700 µg  
geneticin, and was added the following day.  The cells were fed with selective medium  
every 4 days; few weeks later, plates were inspected for colonies.  All cells were grown  
in a humidifier incubator under an atmosphere of 5% CO2.   
Cells were suspended in Tris-buffered saline (25mM Tris base, 138 mM NaCl,  
2.7 mM KCl; pH 7.4) and subjected to 3 rounds of freeze-thaw prior to gentle  
homogenization.  Cell homogenates (5-30 mg homogenate protein/ml) were stored at -70  
°C in 100 µL aliquots.  Total cell homogenate protein concentrations were determined  
using the BCA assay (Pierce Corporation, Rockford, IL).  
 
Western Blot Analysis 
Levels of UGT1A9 expression in UGT1A9-over-expressing cell lines were  
monitored by Western blot analysis using the anti-UGT1A9 antibody in a 1:5000 dilution  
as per the manufacturer’s instructions (Gentest).  Determinations of glucuronide  
formation in wild-type versus variant UGT1A9-over-expressing cell lines were calculated  
relative to the levels of UGT expression in the respective cell lines as determined by  
densitometric analysis (using the AlphaImagerTM 2000 computerized photoimaging  
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Figure 24.  Chemical structure of substrates 
 
 
 
 70
system, Alpha Innotech Corp., San Leandro, CA) of Western blots using the anti- 
UGT1A9 antibody. 
 
Glucuronidating Activity of UGT1A9 (Wild-Type/Polymorphic)-Over-Expressing  
 
Cell Homogenates against NNAL 
The rate of NNAL (Figure 24) glucuronidation by liver microsomes and UGT1A9  
(wild-type and polymorphic variant)-over-expressing cell homogenates was determined  
after a pre-incubation with D,L-2-lysophosphatidyl choline palmital C16:0 (1 mg/mg  
protein) for 10 minutes at 4 °C as previously described. Briefly, liver microsomes (5 mg  
protein) and cell homogenates (3 mg protein) were incubated (100 µL final volume) in 50  
mM Tris-HCl (pH 7.5), 10 mM MgCl2, D,L-2-lysophosphatidyl choline palmital C16:0  
(1 mg/mg protein), 4 mM 14C-UDPGA (1 µCi/100 µL reaction volume), and 5 mM  
NNAL at 37 °C for 2 hours.  Reactions were terminated by the addition of 1/10 volume  
of 0.3 N Ba(OH)2/0.3 N ZnSO4 on ice.  The precipitate was removed by centrifugation,  
and the supernatant was subjected to solid phase extraction on an Oasis HLB 3 cc  
reverse phase cartridge (Waters, Milford, MA) activated with acetonitrile and  
equilibrated with Solvent A (0.05 M NH4AOc; pH 7.0).  After loading onto the cartridge,  
the sample was washed with 1 ml of Solvent A and eluted with 0.5 ml acetonitrile.  The  
acetonitrile was evaporated, the resulting sample diluted to 110 µL with water, and the  
sample was analyzed for glucuronidated NNAL metabolites by HPLC with radioflow  
detection using the following system: a Waters Associates dual-pump (model 510) HPLC  
system (Milford, MA), equipped with an automatic injector (WISP model 710B), a UV  
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detector operated at 254 nm (model 440), and a radioactive flow detector (IN/US  
Systems, Fairfield, NJ).   
HPLC was performed using a 5 µ Aquasil C18 column (4.6 mm X 250 mm,  
Thermo Hypersil-Keystone, Bellefonte, PA) with gradient elution at 1 ml/min using the  
following conditions: 5 min with 100% Solvent A, a linear gradient for 10 min to 30%  
Solvent B (100% methanol), a subsequent linear gradient to 50% Solvent B for 10 min,  
and a final linear gradient to 100% Solvent B for 5 min.  The column was washed for 10  
min with 100% Solvent B and regenerated for 15 min with 100% Solvent A.  14C-NNAL- 
Gluc peaks were confirmed by relative retention time, and in some cases, by sensitivity to  
E.coli β-glucuronidase treatment as previously described. 
 
Glucuronidating Activity of UGT1A9 (Wild-Type/Polymorphic)-Over-Expressing  
 
Cell Homogenates against BPD and other Benzo[a]pyrene Metabolites 
The rate of B[a]P-7,8-dihydrodiol, 1-hydroxy-pyrene, and phenolic BaP  
metabolites (3-, 7-, and 9-hydroxy-BaP) (see Figure 16 for chemical structures) was  
determined using 0.1-1.5 mg UGT1A9-over-expresing cell homogenate (0.1 mg for 3- 
OH-BaP, 0.3 mg for 1-OH-pyrene and 7- and 9-OH-BaP, and1.5 mg for BaP-7,8- 
dihydrodiol).  Cell homogenates were incubated (100 µL final volume) with 1mM 3-, 7-,  
9-OH-BaP or 1-OH-pyrene, or 2mM BaP-7,8-dihydrodiol(±), 4 mM UDPGA, 20 mM  
MgCl2, 50 mM Tris-HCl (pH 7.4).  All reactions were initiated by the addition of  
UDPGA.  Reactions were terminated by the addition of an equal volume of acetonitrile.   
Precipitates were removed by centrifugation (5 min, 10,000 x g) and supernatants were  
filtered and analyzed for glucuronidated BaP metabolites by HPLC using a Beckman  
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HPLC ‘Gold’ System (Fullerton, CA) consisting of a model 110B programmable solvent  
module, a model 166 UV detector operated at 254 nm, a Waters automatic injector  
(model 717 plus) and a β-RAM radioisotope detector (IN/US, Tampa, FL) equipped with  
a 1 ml liquid flow cell.  The samples were injected onto a 201TP (4.6 X 250 mm) 5 µ C18  
300 Å column (VYDAC, Hesperia, CA).  Separations were performed using the  
following linear gradient conditions: 0-5 min, 20% Solvent A; 5-25 min, 20-40% Solvent  
A; 25-30 min, 40-60% Solvent A; 30-35 min, 60-90% Solvent A, where Solvent A was  
acetonitrile and was diluted at the given percentages in Solvent B (20 mM NaH2PO4, pH  
4.6).  The HPLC flow rate was 1 ml/min, while the scintillation fluid flow rate was 4  
ml/min.  The column was routinely washed with 100% Solvent A for 15 min and  
equilibrated after every HPLC run with 20% Solvent A for at least 20 min (see  
procedural flowchart in Figure 25). 
Kinetic analysis for both wild-type and polymorphic UGT1A9-over-expressing  
cell homogenates exhibiting glucuronidating activity against 1-OH-pyrene, 7-OH-BaP,  
and BaP-7,8-dihydrodiol was performed as described above using an incubation time of 2  
hours.  The Km and Vmax for the glucuronidation of 1-OH-pyrene, 7-OH-BaP, and BPD  
by both wild-type and polymorphic UGT1A9 variants were calculated after linear  
regression analysis of Lineweaver-Burk plots. 
 
Statistical Analysis 
The student’s t-test (2-sided) was used for comparing rates of glucuronide  
formation for the UGT1A9183Cys and UGT1A9183Gly isoforms against the different  
substrates examined in this study. 
 73
Total RNA Isolated from UGT1A9-overexpressing cells 
↓ 
RT-PCR  
↓ 
Polyacrylamide Gel Electrophoresis  
↓ 
RT-PCR Product Purification 
↓ 
Dideoxy Sequencing performed to confirm UGT1A9 Wild-Type Sequence 
↓ 
Cloning of Wild-Type UGT1A9 Isoform into Plasmid Vector 
↓ 
Transformation of (Vector + insert) into Chemically Competent E. coli 
↓ 
Transformation product spread on plate (ampicillin-treated) and overnight incubation 
↓ 
Colony Selection and Plasmid DNA Extraction  
↓ 
RFLP Analysis to verify product in correct orientation 
↓ 
Dideoxy Sequencing to confirm UGT1A9 Wild-Type sequence 
 
Figure 25. Procedural flowchart (continued next page) 
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Site-directed mutagenesis using proof-reading polymerase 
↓ 
Transformation of (vector + insert) into competent E. coli 
↓ 
Plasmid DNA extraction after colonies selection 
↓ 
RFLP analysis performed to verify right product 
↓ 
Dideoxy sequencing to confirm UGT1A9 polymorphic sequence 
↓ 
HK293 cells grown and transfected using DNA-Lipofectamine complexes; plate 
inspection for colonies 
↓ 
Cell homogenates prepared from UGT1A9 transfected cells and protein concentration 
determined 
↓ 
Levels of UGT1A9 expression determined by Western blot analysis 
↓ 
Glucuronidation assays performed using various carcinogens/carcinogen metabolites 
↓ 
Levels of UGT enzyme activity determined by HPLC analysis and calculated before and 
after normalization for cell homogenate of UGT1A9 protein levels  
 
Figure 25. Procedural flowchart (continued) 
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Results 
 
Cloning and Sequencing 
  
In order to obtain the whole UGT1A9 sequence, RT-PCR was performed as  
described above, and cloned into the plasmid vector (pcDNA3.1/V5-His- TOPO®).  The  
resulting vector (insert + plasmid) was then transformed into chemically competent E.  
coli, colonies were picked and plasmid DNA extracted to determine whether UGT1A9  
(wild-type) had been cloned.  RFLP analysis was performed using restriction enzyme  
DraI and the digestion results (Figure 26) show that UGT1A9 had been cloned in the  
correct orientation.  To confirm the UGT1A9 wild-type sequence in the plasmid, dideoxy  
sequencing was performed.  The results show that no mutation (Figure 28) occurred  
throughout the sequence matching the original UGT1A9 sequence from Genbank. 
In order to obtain the entire UGT1A9 sequence with only one mutation at codon  
183, site-directed mutagenesis was performed.  After plasmid DNA extraction, RFLP  
analysis was done using restriction enzyme ApaI to check for the right insert with the  
mutation.  ApaI cuts the polymorphic variant (UGT1A9183Gly) twice creating 2 bands on  
the 1% agarose gel, while it cuts the wild-type (UGT1A9183Cys) only once, creating only 1  
band (Figure 27).  To confirm the UGT1A9 polymorphic sequence in the plasmid,  
dideoxy sequencing was performed.  The results show that only one mutation at codon  
183 (Figure 28), changing TGC to GGC (Cysteine to Glycine), is present throughout the  
sequence.  The rest of the sequence matched the wild-type sequence. 
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Figure 26.  RFLP analysis using restriction enzyme DraI (correct orientation observed) 
(vector size = 5523 b.p.; UGT1A9 size = 1627 bp)                                                       
(WT: WildType) 
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Figure 27.  RFLP analysis using restriction enzyme ApaI (to check for polymorphic vs. 
wild-type) (vector size = 5523 b.p.; UGT1A9 size = 1627 bp)                                      
(WT: WildType and Poly: Polymorphic) 
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Homozygous wild-type 
 
 
 
 
Homozygous polymorphic 
 
 
 
Figure 28.  Section of the entire UGT1A9 sequence showing both the homozygous wild-
type (with no mutation) and the homozygous polymorphic identified by sequencing 
analysis (only one mutation at codon 183 changing TGC to GGC)                     
(homozygous is defined as containing two copies of the same allele) 
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Western Blot Analysis 
Levels of UGT1A9 expression in UGT1A9-over-expressing cell lines were  
monitored by Western blot analysis.  The levels of UGT1A9 expression in the respective  
cell lines (wild-type versus variant) were determined by densitometric analysis using  
UGT1A protein as standard (Figure 29).  The results indicate that the UGT1A9183Gly  
isoform has at least three times the level of expression compared to the UGT1A9183Cys.   
 
NNAL Glucuronidation in UGT1A9-Over-Expressing Cell Homogenates (Wild-type  
 
vs. Polymorphic Variant) 
Previous studies have demonstrated that UGT1A9 exhibited glucuronidating  
activity against NNAL (Qing et al., 2000).  To determine whether the change in amino  
acid sequence at codon 183 results in a change in UGT1A9 enzyme activity, 
glucuronidation assays were performed using equal amounts of total cell protein against  
NNAL.  Levels of UGT enzyme activity were determined in three separate experiments  
by HPLC analysis and calculated both before and after normalization for cell homogenate  
of UGT1A9 protein levels as determined by Western blot analysis.  Although high levels  
of activity were observed for the wild-type UGT1A9183Cys variant against NNAL, none  
was detected in assays with the UGT1A9183Gly variant (Figure 30). 
 
BPD and other Benzo[a]pyrene metabolites in UGT1A9-Over-Expressing Cell  
 
Homogenates (Wild-type vs. Polymorphic Variant) 
Previous studies have demonstrated that UGT1A9 exhibited glucuronidating  
activity against benzo[a]pyrene-7,8-dihydrodiol, 3-, 7-, 9-hydroxy-benzo[a]pyrene, and 
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Figure 29.  Western blot                                                                             
(WT: Wildtype and Poly: Polymorphic) 
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A 
 
 
B 
 
 
C 
 
Figure 30.  HPLC analysis of NNAL-Gluc formation in liver and UGT1A9-over-
expressing HK293 cells.  A, Human liver microsomes were incubated using 4 mM 14C-
UDPGA and 5 mM NNAL as described under Materials and Methods.  B, 14C-labeled 
metabolites from incubations using homogenates from wild-type UGT1A9-over-
expressing cells.  C, 14C-labeled metabolites from incubations using homogenates from 
polymorphic UGT1A9-over-expressing cells.                                                            
14C-UDPGA 
    Retention Time (min) 
14C-UDPGA 
Retention Time (min) 
14C-UDPGA 
Retention Time (min) 
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Figure 31.  HPLC analysis of BPD-Gluc formation in homogenates from UGT1A9-over-
expressing HK293 cells.  A, metabolites from incubations using homogenates from wild-
type UGT1A9-over-expressing cells.  B, metabolites from incubations using 
homogenates from polymorphic UGT1A9-over-expressing cells. 
UV Absorbance 
Retention Time (min) 
UV Absorbance 
Retention Time (min)
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Before UGT protein normalization 
 Rate (pmol/mg/min)  
Glucuronides of 
substrates 
Mean (wt) Mean (poly) Two-tailed p 
value (α = 0.05) 
Ratio (poly/wt) 
B[a]P-7,8-diol-
Gluc 
7.76 7.36 0.0428 0.95 
3-O-Gluc-
B[a]P 
82.72 70.06 0.0612 0.85 
7-O-Gluc-
B[a]P 
102.52 95.73 0.0973 0.93 
9-O-Gluc-
B[a]P 
26.68 24.06 0.0190 0.90 
1-O-Gluc-
pyrene 
153.8 187.84 0.0052 1.22 
 
After UGT protein normalization 
 Rate (pmol/µg/min)  
Glucuronides of 
substrates 
Mean (wt) Mean (poly) Two-tailed p 
value (α = 0.05) 
Ratio (poly/wt) 
B[a]P-7,8-diol-
Gluc 
41.55 12.62 < 0.0001 0.30 
3-O-Gluc-
B[a]P 
442.87 120.16 < 0.0001 0.27 
7-O-Gluc-
B[a]P 
548.88 164.18 < 0.0001 0.30 
9-O-Gluc-
B[a]P 
142.84 41.26 < 0.0001 0.29 
1-O-Gluc-
pyrene 
823.43 322.16 < 0.0001 0.39 
 
Table 7.  Rates of UGT1A9183Cys (wild-type) and UGT1A9183Gly (polymorphic) variant 
against all substrates before and after protein normalization                                               
(WT: Wildtype and Poly: Polymorphic)    
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1-hydroxy-pyrene (Fang et al., 2002).  To determine whether the change in amino acid  
sequence at codon 183 results in a change in UGT1A9 enzyme activity, glucuronidation  
assays were performed using equal amounts of total cell protein against each of the  
mentioned substrates (Figure 31).  Levels of UGT enzyme activity were determined in  
three separate experiments by HPLC analysis and calculated both before and after  
normalization for cell homogenate of UGT1A9 protein levels as determined by Western  
blot analysis. 
Significant decreases in activity were observed for the UGT1A9183Gly variant prior  
to UGT protein normalization in assays using 9-OH-BaP or BaP-7,8-diol (p<0.05) as  
substrate.  After UGT protein normalization, significant decreases in activity (p<0.0001)  
were observed for the UGT1A9183Gly variant in assays using all substrates (Table 7). 
 
Kinetic Analysis (Km and Vmax Study) 
The Km and Vmax for the glucuronidation of benzo[a]pyrene-7,8-dihydrodiol, 7- 
OH- benzo[a]pyrene, and 1-OH-pyrene were calculated after linear regression analysis of  
Lineweaver-Burk plots for both UGT1A9183Cys and UGT1A9183Gly variants (Figure 32,  
33, and 34).  The affinities and rates for each of the substrates as reflected by the apparent  
Km and Vmax were UGT1A9183Cys > UGT1A9183Gly as summarized in Table 8. 
 
Discussion 
This is the first study to functionally characterize the UGT1A9183Gly polymorphic  
variant.  The levels of UGT1A9 activity that were determined by HPLC analysis and  
calculated after normalization for cell homogenate of UGT1A9 protein levels, as  
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A (Homozygous wild-type) 
 
 
 
B (Homozygous polymorphic) 
 
Figure 32.  Linear regression analysis of Lineweaver-Burk plots for both UGT1A9183Cys 
(A) and UGT1A9183Gly variants (B) using Benzo[a]pyrene-7,8-dihydrodiol as substrate 
(done in triplicates using 1mM, 0.5 mM, 0.25 mM, 0.15 mM, and 0.05 mM of substrate) 
(Homozygous is defined as containing two copies of the same allele; V: Velocity and S: 
Substrate) 
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A (Homozygous wild-type) 
 
 
B (Homozygous polymorphic) 
 
Figure 33.  Linear regression analysis of Lineweaver-Burk plots for both UGT1A9183Cys 
(A) and UGT1A9183Gly variants (B) using 7-OH-Benzo[a]pyrene as substrate (done in 
triplicates using 0.25 mM, 0.1 mM, 0.05 mM, 0.025 mM, 0.01 mM, and 0.005 mM of 
substrate)                                                                                         
(Homozygous is defined as containing two copies of the same allele; V: Velocity and S: 
Substrate) 
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A (Homozygous wild-type) 
 
 
B (Homozygous polymorphic) 
 
Figure 34.  Linear regression analysis of Lineweaver-Burk plots for both UGT1A9183Cys 
(A) and UGT1A9183Gly variants (B) using 1-OH-pyrene as substrate (done in triplicates 
using 0.25 mM, 0.1 mM, 0.05 mM, 0.025 mM, 0.01 mM, and 0.005 mM of substrate) 
(Homozygous is defined as containing two copies of the same allele; V: Velocity and S: 
Substrate) 
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 Km values (µM)  
Substrate UGT1A9183Cys 
(wild-type) 
UGT1A9183Gly 
(polymorphic) 
Two-tailed p     
value (α = 0.05) 
BaP-7,8-diol 207.44 600.11 0.0012 
7-OH-BaP 73.19 104.42 0.0798 
1-OH-pyrene 14.0 17.81 0.1105 
 Vmax values   
Substrate UGT1A9183Cys 
(wild-type) 
UGT1A9183Gly 
(polymorphic) 
Two-tailed p     
value (α = 0.05) 
BaP-7,8-diol 6.00 4.28 0.0470 
7-OH-BaP 183.87 157.40 0.1711 
1-OH-pyrene 169.56 155.41 0.1842 
 
Table 8.  Affinities and rates for each of the substrates as reflected by the apparent Km 
and Vmax (all numbers in the table are calculated using the average of three reactions) 
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determined by Western blot analysis, show that the UGT1A9183Gly polymorphic variant  
exhibits a significantly lower enzyme activity (p < 0.0001) than the wild-type variant,  
UGT1A9183Cys, for all benzo[a]pyrene metabolites tested (BaP-7,8-dihydrodiol, 3-, 7-,  
and 9-OH-BaP, and 1-OH-pyrene).  No activity was detected against NNAL in assays  
with the UGT1A9183Gly variant.   
These results are consistent with the Km and Vmax values calculated which show  
that the polymorphic variant, UGT1A9183Gly, has a higher Km value, which means lower  
affinity, for all substrates tested with the Km value for BaP-7,8-dihydrodiol being   
significantly higher for the UGT1A9183Gly variant.  The Michaelis constant, Km, is  
associated with the affinity of enzyme for substrate; a larger Km means that the enzyme  
binds the substrate weakly.  Thus, when the rate of product formation is low, Km can be  
thought of as an inverse measure of substrate binding strength.  The results are also  
consistent with the Vmax values calculated which show that the polymorphic variant, 
UGT1A9183Gly, has a lower Vmax value, for all substrates tested with the Vmax value for  
BaP-7,8-dihydrodiol being significantly lower for the UGT1A9183Gly variant.  The Vmax  
is defined as the maximal rate at which an enzyme catalyzes a reaction. It is expressed as  
the amount of product formed per minute.  The Vmax is achieved when all the enzyme  
active sites are occupied with substrate molecules. This condition is called substrate  
saturation.  
UGT1A9 has been shown to play an important role in the phase II metabolism of  
procarcinogenic metabolites of benzo[a]pyrene (BaP), 4-(methylnitrosamino)-1-(3- 
pyridyl)-1-butanone (NNK) and other carcinogens/carcinogen metabolites.  As  
previously mentioned,  Benzo[a]pyrene is a much-studied polycyclic aromatic  
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hydrocarbon that exhibits high carcinogenicity in animals and is found widespread in the  
environment including in emission exhausts, cigarette smoke, and char-broiled foods  
(Gelboin et al., 1980; IARC, General remarks 1983; Dipple et al., 1990).  In addition, the  
nicotine derived nitrosamine, NNK, is one of the most potent and abundant  
procarcinogens found in tobacco and tobacco smoke (Hecht et al., 1989; Hecht et al.,   
1998).  Its levels in tobacco smoke are 3- 15 times higher than that of benzo[a]pyrene  
(Adams et al., 1987).   
Therefore, the results of this study demonstrate that the UGT1A9 (Cys183Gly)  
polymorphism significantly alters UGT1A9 function and could potentially play an  
important role as a risk modifier for digestive tract cancers.    
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